FTH Faeth Therapeutics, Inc.
$18.02▼ -3.89%
Healthcare
Other
Volume 394.8K
Avg Volume (10D) 433.9K
Key Metrics & Fundamentals
Market Cap
$465.64M
P/E Ratio
–
Div Yield
0.00%
52W Range
7.45 - 42.14
% vs 50 MA
-35.50%
% vs 200 MA
-25.32%
RSI-14
34.9
MACD Histogram
+0.0900
Beta (1Y vs SPY)
2.38
Free Cash Flow
-$15.67M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$18.36M
COGS
–
Operating Exp
$18.39M
Operating Income
-$18.39M
EBIT
-$18.39M
Pretax Income
-$16.01M
Net Income
-$16.01M
EPS (Diluted)
-2.84
Price & Volume History
Loading chart…
Recent News
Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors
Business Wire · Oct 27, 2026 7:00 AM ET
Faeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against Gedatolisib
Business Wire · Oct 23, 2026 9:15 AM ET
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire · Oct 22, 2026 4:05 PM ET
William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage
Business Wire · Oct 21, 2026 12:30 PM ET
Faeth to Present Preclinical Data on PIKTOR in HR+/HER2- Breast Cancer Models at ESMO 2026
Business Wire · Oct 19, 2026 7:30 AM ET
William Blair Initiates Coverage on Faeth Therapeutics With Outperform Rating
MT Newswires · Oct 16, 2026 7:32 AM ET
Faeth Therapeutics' PIK-201 Readout to Serve as Major Inflection Point, Oppenheimer Says
MT Newswires · Oct 7, 2026 12:45 PM ET
Sensei Biotherapeutics Highlights PIKTOR Strategy Ahead of Endometrial Trial Readout
MarketBeat · Oct 7, 2026 4:02 AM ET
Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors
Business Wire · Sep 17, 2026 4:00 PM ET
Guggenheim Initiates Faeth Therapeutics at Buy With $70 Price Target
MT Newswires · Sep 16, 2026 6:53 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See FTH's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.